Retinal Degeneration
30 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 1.5 x 10^6 UC-MSC + CM for retinitis pigmentosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 5 x 10^6 UC-MSC + CM for retinitis pigmentosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AAV2-hRPE65v2,voretigene neparvovec-rzyl for retinitis pigmentosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ACDN-01 for cone-rod dystrophies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ACDN-01 for stargardt disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ADVM-022 for wet macular degeneration | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autologous iPSC-derived RPE for macular degeneration | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brinretigene Vesgedparvovec for retinal degeneration | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BS01 for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eyecyte-RPE™ for geographic atrophy | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE) for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NT-101 ophthalmic solution for macular degeneration | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 High Dose for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 High Dose + OCU400 Med Dose for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 Low Dose for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 Med Dose for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 Second Eye Dosing for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU410 for geographic atrophy | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OLN324 for macular degeneration | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OpRegen for geographic atrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OpRegen for macular degeneration | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prima for geographic atrophy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PRIMA Bionic Vision System for geographic atrophy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| PRIMA Products for retinitis pigmentosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PRIMA Products for stargardt disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PST-611 for geographic atrophy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Puliretgene Parvec for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| rAAV2.REP1 for retinitis pigmentosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RTx-015 for retinitis pigmentosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SB-007 for stargardt disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |